Skip to main content
Premium Trial:

Request an Annual Quote

The Old Life Isn't Fair Thing Pops to Mind

After reading a primer in Nature Biotechnology that discussed principal component analysis, often used in genome-wide expression studies, blogger Neil Saunders realized he'd read several blog posts on that topic as well. But, he points out, the author of the Nature Biotechnology article receives credit from the academic community while the bloggers most likely do not. "It doesn't seem right to me. How does your institution evaluate and reward "non-traditional" output?" asks Saunders.

The Scan

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.